User:Dileep D. Monie: Difference between revisions
From OpenWetWare
Jump to navigationJump to search
mNo edit summary |
m (→Contact Info) |
||
(26 intermediate revisions by the same user not shown) | |||
Line 1: | Line 1: | ||
==Contact Info== | ==Contact Info== | ||
[[Image:Dileep.jpg|thumb|right|Dileep D. Monie]] | |||
[[Image: | |||
*Dileep Monie | *Dileep D. Monie | ||
* | **[http://scholar.harvard.edu/dmonie Teaching Fellow, Harvard University] | ||
* | **[https://www.broadinstitute.org/directory/?usersearch=Dileep+Monie&usearch=Search Associated Researcher, Broad Institute of MIT and Harvard] | ||
*[ | **[[BUGSS|Director & Secretary, Baltimore Under Ground Science Space (BUGSS)]] | ||
I learned about [[OpenWetWare]] from | I learned about [[OpenWetWare]] from [http://events.ccc.de/congress/2007/Fahrplan/events/2329.en.html Drew Endy's 24C3 lecture], and I've joined because I am interested in making biology easier to engineer. Please feel free to [[Special:Emailuser/Dileep D. Monie|contact me on OWW]] or [http://www.linkedin.com/in/dmonie connect on LinkedIn]. | ||
<!-- | <!-- | ||
==Research Interests== | ==Research Interests== | ||
# Synthetic Biology | # Synthetic Biology | ||
## | ## Standards - Establishing standards for biological parts to ensure interoperability and allow for construction of complex systems | ||
## Biocircuits - Implementing wetware abstraction layers to allow creation of devices for cellular computation and communications | ## Biocircuits - Implementing wetware abstraction layers to allow creation of devices for cellular computation and communications | ||
## Epigenetics - Manipulating chromatin structures with histone and DNA modifications as a form of biological software programming | ## Epigenetics - Manipulating chromatin structures with histone and DNA modifications as a form of biological software programming | ||
Line 28: | Line 26: | ||
## Countermeasures - Designing fail-safe mechanisms to mitigate potential synthetic biology abuses | ## Countermeasures - Designing fail-safe mechanisms to mitigate potential synthetic biology abuses | ||
--> | --> | ||
==BBF Contributions== | ==BBF Contributions== | ||
* [[/Notebook/BBF_Standards_Measurement|Promoter Measurement Test]] | *[[The_BioBricks_Foundation:Standards/Technical|Technical Standards]] | ||
*[[/Notebook/BBF_Standards_Measurement|Promoter Measurement Test]] | |||
==OWW Brain Dump== | ==OWW Brain Dump== | ||
Line 36: | Line 36: | ||
*[http://openwetware.org/index.php?title=Special%3ALog&type=upload&user=Dileep+D.+Monie Upload log] | *[http://openwetware.org/index.php?title=Special%3ALog&type=upload&user=Dileep+D.+Monie Upload log] | ||
==Publications== | ==Publications== | ||
<biblio> | <biblio> | ||
Line 42: | Line 41: | ||
#Paper2 pmid=10441117 | #Paper2 pmid=10441117 | ||
#Paper3 pmid=19298678 | #Paper3 pmid=19298678 | ||
#Paper4 pmid=21212284 | |||
#Book1 isbn=9780781764964 | #Book1 isbn=9780781764964 | ||
// Contributed section on "Pulmonary Hypertension" (pp. 148-9) | // Contributed section on "Pulmonary Hypertension" (pp. 148-9) | ||
</biblio> | </biblio> | ||
Revision as of 14:58, 29 September 2015
Contact Info
- Dileep D. Monie
I learned about OpenWetWare from Drew Endy's 24C3 lecture, and I've joined because I am interested in making biology easier to engineer. Please feel free to contact me on OWW or connect on LinkedIn.
BBF Contributions
OWW Brain Dump
Publications
- Monday SR, Vath GM, Ferens WA, Deobald C, Rago JV, Gahr PJ, Monie DD, Iandolo JJ, Chapes SK, Davis WC, Ohlendorf DH, Schlievert PM, and Bohach GA. Unique superantigen activity of staphylococcal exfoliative toxins. J Immunol. 1999 Apr 15;162(8):4550-9.
- Vath GM, Earhart CA, Monie DD, Iandolo JJ, Schlievert PM, and Ohlendorf DH. The crystal structure of exfoliative toxin B: a superantigen with enzymatic activity. Biochemistry. 1999 Aug 10;38(32):10239-46. DOI:10.1021/bi990721e |
- Kelly JR, Rubin AJ, Davis JH, Ajo-Franklin CM, Cumbers J, Czar MJ, de Mora K, Glieberman AL, Monie DD, and Endy D. Measuring the activity of BioBrick promoters using an in vivo reference standard. J Biol Eng. 2009 Mar 20;3:4. DOI:10.1186/1754-1611-3-4 |
- Oh U, McCormick MJ, Datta D, Turner RV, Bobb K, Monie DD, Sliskovic DR, Tanaka Y, Zhang J, Meshulam J, and Jacobson S. Inhibition of immune activation by a novel nuclear factor-kappa B inhibitor in HTLV-I-associated neurologic disease. Blood. 2011 Mar 24;117(12):3363-9. DOI:10.1182/blood-2010-10-306571 |
- ISBN:9780781764964
Contributed section on "Pulmonary Hypertension" (pp. 148-9)